Shots: The P-III A4091059 study involves assessing of tanezumab (5mg,10mg) vs PBO vs tramadol (prolonged release) in 1,832 in the ratio 2:2:2:3 with moderate-to-severe chronic low back pain (CLBP) in […]readmore
Tags : A4091059
Latest Posts
Categories
Related Topics
AbbVie
Acceptance
Acquire
Agreement
Amgen
approval
AstraZeneca
Bayer
Biosimilar
BMS
Boehringer Ingelheim
Collaborates
Collaboration
Commercialize
COVID-19
Develop
Development
Eli Lilly
Exclusive
FDA
Gilead
GSK
Janssen
Launches
License
License Agreement
Lilly
Merck
Novartis
P-III
patients
Pfizer
receives
Regeneron
Report
reports
results
Roche
Sanofi
Signs
study
Takeda
Treat
Treatment
US